Suda Ltd Share Price Australian S.E.
Equities
EMS
AU000000EMS2
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- AUD | - |
|
06-13 | Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement | MT |
06-05 | Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9% | MT |
Sales 2022 | 296K 197K 15.52M | Sales 2023 | 1.45M 970K 76.33M | Capitalization | 42.5M 28.35M 2.23B |
---|---|---|---|---|---|
Net income 2022 | -8M -5.34M -420M | Net income 2023 | -10M -6.67M -525M | EV / Sales 2022 | 32 x |
Net cash position 2022 | 5.93M 3.95M 311M | Net cash position 2023 | 5.18M 3.45M 272M | EV / Sales 2023 | 25.7 x |
P/E ratio 2022 |
-1.47
x | P/E ratio 2023 |
-3.49
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.45% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Baker
CEO | Chief Executive Officer | - | 01/01/20 |
Tim Luscombe
DFI | Director of Finance/CFO | - | 11-30 |
Michelle Long
ADM | Chief Administrative Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 62 | 30/06/22 |
Elizabeth Stoner
BRD | Director/Board Member | 73 | 09/11/21 |
Thomas Duthy
CHM | Chairman | - | 12/03/23 |
1st Jan change | Capi. | |
---|---|---|
+34.01% | 51.07B | |
+33.84% | 38.86B | |
-8.02% | 38.78B | |
-8.98% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- ALA Stock
- EMS Stock